Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
about
Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionPhase II study of sorafenib in patients with relapsed or refractory lymphoma.Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateAntibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaA phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.Angiogenesis and melanoma - from basic science to clinical trials.Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.Systemically administered liposome-encapsulated Ad-PEDF potentiates the anti-cancer effects in mouse lung metastasis melanomaUnderstanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Chemotherapy in the management of advanced cutaneous malignant melanoma.Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).Fotemustine for the treatment of melanoma.A new era in the treatment of melanoma: from biology to clinical practice.Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes.Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.Inhibition of angiogenesis for the treatment of metastatic melanoma.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.Melanoma & biomarkers of immunoresponsiveness
P2860
Q28728389-FA2A04BF-9E14-4DDE-B28D-3F526E51B0E0Q33401136-B645CCB1-162E-446D-BAE4-925EC089B4B7Q33757046-5C76D206-55C5-4FD3-9003-ACDB7A32FEEAQ33887664-CDEB10FF-6BDE-4FA6-9583-8FB02B1AF9B6Q34000700-E994EA6D-A347-48E1-968E-BBE5954D639EQ34497045-DC7C6401-DEB6-4EB4-8F5E-6BAE1C8E3D35Q35050558-12B5D5E9-8442-40D9-A8F7-7BB7189CE6D2Q35380959-962805D5-1C53-4CD9-8DC4-E2D86AF98332Q35541507-EEC259F4-3D6F-4719-9FB7-51085859FA1AQ35923178-ED65C15A-7171-4422-86C8-7AD86B99FECDQ36687470-4B0D5B51-74AF-4FB2-9E75-A974E560AD5BQ36799390-6E1E9E2A-418A-4756-A6E7-53DC3750B99FQ36808641-8A4468D0-86E5-4898-96DE-1E94D6297F0EQ37007984-7E820D33-DBE5-4ABC-BA68-264356F56DDEQ37526275-A88F235B-68CB-478F-9645-F287D7BCF2CCQ37955277-06625F6A-73E8-4EFE-A272-4D3AD46726E5Q37956047-56C54749-F0B4-4EEF-98F7-A96B0A206784Q38072488-4E3C4182-C03F-43B4-9F9A-8289BEE7A7E7Q38096437-B30D8A7E-7E07-4ECD-B0AD-D5C8698BAD6CQ38134302-743E4BF8-C180-4C26-AAB4-213EC236CCEDQ38195656-36834012-C59B-405B-BBCA-B67C2AB30D61Q38196881-51653899-58C9-42FB-837D-80A69A680082Q38749030-A7284A98-58F6-4C5B-B501-F34A4E23ED32Q52149377-CCC72DFA-5DE7-41C7-BD84-044003175E90Q58234468-19D1C619-FD0C-4B22-AF94-BC53DA0BA187
P2860
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@en
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@nl
type
label
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@en
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@nl
prefLabel
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@en
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors.
@nl
P2093
P50
P1476
Bevacizumab plus fotemustine a ...... and lymphangiogenesis factors
@en
P2093
Emilio Bajetta
Mario R Sertoli
Nicola Pimpinelli
Paola Morosini
Stefania Canova
Tania Perrone
P304
P356
10.1158/1078-0432.CCR-10-2363
P407
P50
P577
2010-10-28T00:00:00Z